Published in J Exp Med on January 01, 1995
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol (1997) 2.50
Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med (1996) 2.19
A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med (2004) 1.81
Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol (2001) 1.67
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin. Infect Immun (1996) 1.60
Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med (1997) 1.59
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med (2007) 1.57
Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun (1998) 1.57
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol (1996) 1.49
Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2001) 1.39
Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21. J Immunol (2006) 1.19
Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med (1997) 1.14
Cytokine modulation alters pulmonary clearance of Rhodococcus equi and development of granulomatous pneumonia. Infect Immun (1995) 1.14
Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest (1995) 1.12
Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog (2008) 1.11
Human immunodeficiency virus and leishmaniasis. J Glob Infect Dis (2010) 1.09
Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut (1998) 1.05
Transfer of a CD4+ Th1 cell line to nude mice effects clearance of Rhodococcus equi from the lung. Infect Immun (1996) 1.05
Intracellular Salmonella dublin induces substantial secretion of the 40-kilodalton subunit of interleukin-12 (IL-12) but minimal secretion of IL-12 as a 70-kilodalton protein in murine macrophages. Infect Immun (1997) 1.02
Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother (2003) 0.99
CD2 regulates responsiveness of activated T cells to interleukin 12. J Exp Med (1995) 0.97
Regulation of immunity during visceral Leishmania infection. Parasit Vectors (2016) 0.92
Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect Immun (2003) 0.92
Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental coccidioidomycosis. Infect Immun (1999) 0.91
Activation of phosphatidylinositol 3-kinase/Akt and impairment of nuclear factor-kappaB: molecular mechanisms behind the arrested maturation/activation state of Leishmania infantum-infected dendritic cells. Am J Pathol (2010) 0.90
Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18. Infect Immun (2006) 0.90
Limited interleukin-18 response in Salmonella-infected murine macrophages and in Salmonella-infected mice. Infect Immun (1999) 0.89
Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response. PLoS Negl Trop Dis (2010) 0.88
Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections. J Virol (1997) 0.88
Progression of visceral leishmaniasis due to Leishmania infantum in BALB/c mice is markedly slowed by prior infection with Trichinella spiralis. Infect Immun (1997) 0.86
Invariant NKT cells drive hepatic cytokinic microenvironment favoring efficient granuloma formation and early control of Leishmania donovani infection. PLoS One (2012) 0.86
Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani. J Trop Med (2011) 0.84
Natural killer cells in experimental and human leishmaniasis. Front Cell Infect Microbiol (2012) 0.82
Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest (1998) 0.80
Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection. Infect Immun (2014) 0.77
Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection. Infect Immun (1996) 0.77
CD4+ Recent Thymic Emigrants Are Recruited into Granulomas during Leishmania donovani Infection but Have Limited Capacity for Cytokine Production. PLoS One (2016) 0.75
Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A (1993) 6.87
Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A (1993) 6.33
Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med (1993) 5.75
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 5.71
Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med (1993) 4.49
Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B-17 mice. Reversal by IFN-gamma. J Immunol (1994) 3.50
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med (1994) 2.99
IL-12: initiation cytokine for cell-mediated immunity. Science (1993) 2.97
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 2.84
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun (1994) 2.48
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
Interleukin-12 enhances murine survival against acute toxoplasmosis. Infect Immun (1994) 2.39
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci U S A (1993) 2.08
Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol (1988) 1.87
Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol (1989) 1.70
Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun (1994) 1.67
Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol (1994) 1.43
Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother (1994) 1.41
Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J Infect Dis (1990) 1.37
Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol (1993) 1.29
Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med (1994) 1.05
Circulating Borrelia burgdorferi in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. J Infect Dis (1993) 1.88
Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest (1989) 1.67
Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol (1994) 1.43
Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med (1997) 1.14
Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest (1995) 1.12
Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother (1993) 1.07
Antimicrobial response of a T cell-deficient host to cytokine therapy: effect of interferon-gamma in experimental visceral leishmaniasis in nude mice. J Infect Dis (1995) 0.97
Models of relapse of experimental visceral leishmaniasis. J Infect Dis (1996) 0.97
Use of electively cryopreserved microsurgically aspirated epididymal sperm with IVF and intracytoplasmic sperm injection for obstructive azoospermia. Fertil Steril (2000) 0.86
Induction of macrophage antiprotozoal activity by monocyte chemotactic and activating factor. FEMS Immunol Med Microbiol (1996) 0.86
Response to treatment for an intracellular infection in a T cell-deficient host: toxoplasmosis in nude mice. J Infect Dis (1993) 0.86
Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob Agents Chemother (1996) 0.83
H-Y antigen expression patterns in human X- and Y-chromosome-bearing spermatozoa. Am J Reprod Immunol (1998) 0.80
Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis. Am J Trop Med Hyg (1996) 0.78
Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection. Infect Immun (1996) 0.77